New treatment for cervical cancer resistant to chemotherapy and radiation
Official title: Novel Antimicrobial Approach to Treat Chemoradiation Resistant Cervical Cancer by Selectively Inhibiting Lactobacillus iners
Funded at Osel, INC. · NIH-11062829 · Data updated 2026-11-12
This study is exploring a new way to help women with cervical cancer that doesn't respond to regular treatments by using a special substance to target harmful bacteria, which could make existing treatments work better.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Osel, INC. NIH-funded |
| Lab location | 1 site (Mountain View, United States) |
| Project start | May 20, 2025 |
| Project end | April 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $295,881 |
| NIH project number | 1R43CA297979-01 |
| Project ID | NIH-11062829 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are women diagnosed with cervical cancer who are experiencing resistance to chemoradiation treatments.
✕Less likely to help
Patients with cervical cancer who are not resistant to chemoradiation or those with other types of cancer may not benefit from this research.
What this research studies
This research investigates a novel antimicrobial approach to treat cervical cancer that does not respond to traditional chemotherapy and radiation. It focuses on a specific bacteriocin, GasK7B, which selectively inhibits Lactobacillus iners, a bacteria that can hinder treatment effectiveness. The study will synthesize this bacteriocin and evaluate its ability to enhance the effectiveness of existing cancer treatments in laboratory models. By targeting the harmful bacteria while preserving beneficial ones, this approach aims to improve outcomes for women with cervical cancer.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option that enhances the effectiveness of chemotherapy and radiation for cervical cancer patients.
How similar studies have gone: While this approach is novel, previous research has shown promise in using bacteriocins for targeted antimicrobial therapy, suggesting potential for success.
Where this research is happening
-
Osel, INC.
Mountain View, United States Active
Researchers
- Principal investigator: Lagenaur, Laurel a. — Osel, INC.
- Study coordinator: Lagenaur, Laurel a.
Related research
Other NIH-funded projects on the same topics.
-
Community and digital tools to reduce HPV and cervical cancer burden
A nurse or health team will test a community-based, digital strategy to help girls and young women, especially in rural areas, get HPV vaccination and cervical cancer prevention services.
-
Community and digital tools to reduce HPV and cervical cancer in women with HIV
A community- and digital-technology program aims to help girls and young women, including those with HIV, get more HPV vaccination and cervical cancer prevention services.
-
mSaada: a mobile tool to boost cervical cancer screening in western Kenya
A mobile app helps community health volunteers manage cervical cancer screening tasks and follow-up for women in low-resource areas.
-
Globally useful predictor for cervical cancer treatment response
This project aims to develop a simple predictive signature to personalize treatment for locally advanced cervical cancer using easy tests and imaging.
-
HPV self-collection in HIV care to screen for cervical cancer in Ethiopia
A patient-centered program tests a simple HPV self-collection approach within HIV clinics in Ethiopia to help detect cervical cancer earlier.
-
Hybrid approach to boost cervical cancer screening in Uganda
A tested, community-driven program helps Ugandan women encourage their peers to get free VIA cervical cancer screening.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.